Identifying New Therapeutics

Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.

Qisheng Zhang portrait

Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.

UNC Eshelman School of Pharmacy Associate Professor Qisheng Zhang was recently awarded a $2,247,857 grant from the National Cancer Institute to study mutations in lymphomas and leukemias with the goal of identifying new therapeutics.

The four-year grant will support his work, “A high-throughput platform to identify selective allosteric inhibitors of the PLC-g isozymes.” Co-investigators on the study include Eshelman faculty John Sondek and Kenneth Pearce Jr.

“Our goal is to discover selective inhibitors to further understand how hyperactive PLC-g proteins drive cancer and ultimately to develop novel approaches to treat leukemias and lymphomas,” Zhang said.

Read the complete Carolina Story…Opens in new window


UNC Eshelman School of Pharmacy Funding Priorities

Readers Also Viewed...

Dr. David Drewry

Collaborating for a Cure

Drug treatments for a rare form of cancer have eluded researchers for years. Work at the UNC Eshelman School of Pharmacy has scientists and survivors optimistic that big breakthroughs are within reach.

Two scientists look at test tubes

Fighting Future Pandemics

SAS Joins READDI in the Fight to Prevent Future Pandemics

Pharmacists practicing to administer a vaccine.

Future Pharmacists at the Ready

“We are preparing ourselves… to be key administers of this vaccine.”


Discovering Disease Treatments

Strengthening neuroscience research


READDI for the Future

“READDI has the potential to make sure we are never caught off-guard again.”

Global Pharmacy Scholars at Keio University in Tokyo, Japan
Global Impact

Global rotations

The Global Pharmacy Scholars (GPS) program is a springboard to creating innovative solutions for global health care issues.